Relief Therapeutics Chairman Sees Covid-19 Drug Earning Millions

Relief Therapeutics’s chairman says the Swiss biotech stands to earn hundreds of millions of dollars if its drug Aviptadil gets a green light from regulators for treating Covid-19, according to an interview with The Market.

Even with a vaccine, it’ll take some time to get people around the world inoculated, “so our drug would have a potential four to six years of use for patients who are seriously ill, and it could generate hundreds of millions of dollars per year during that time,” Chairman Raghuram Selvaraju was quoted as saying.

The shares jumped more than 1,600% this week, when ...